Article Details
Retrieved on: 2023-10-16 16:02:14
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
(AstraZeneca). The two companies will jointly conduct a registrational Phase III study of the Bcl-2 inhibitor, APG-2575 (lisaftoclax), in combination ...
Article found on: www.marketscreener.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here